Semrush (SEMR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $97.4 million, up 24% year-over-year, surpassing guidance and driven by increased paying customers and higher revenue per customer.

• Non-GAAP operating income was $12.1 million with a 12.4% margin, up nearly 300 basis points year-over-year; net income attributable to the company was $1.1 million.

• Over 117,000 paying customers as of September 30, 2024, up from over 106,000 a year earlier, with strong enterprise demand and major new deals from global brands.

• Three acquisitions completed in 2024—Exploding Topics, Ryte, and Brand 24—expanded product offerings and customer base.

• Continued innovation in AI-powered marketing tools and successful launch of Enterprise SEO product.

Financial highlights

• Annual recurring revenue (ARR) grew 24% year-over-year to $401 million; average ARR per paying customer now exceeds $3,400, up 13% year-over-year.

• Q3 2024 operating income was $1.7 million; non-GAAP operating margin was 12.4%; gross margin for Q3 was approximately 82%.

• Free cash flow for the nine months ended September 30, 2024, was $25.8 million, up from negative $8.5 million in the prior year.

• Cash and equivalents plus short-term investments totaled $233 million at quarter end.

• Net cash provided by operating activities for the nine months ended September 30, 2024, was $35.1 million.

Outlook and guidance

• Q4 2024 revenue expected between $100.8 million and $101.8 million, representing ~21% year-over-year growth at midpoint.

• Full-year 2024 revenue guidance raised to $375–$376 million, up 22% at midpoint; non-GAAP operating margin for 2024 expected at ~12%; free cash flow margin at ~8%.

• Management expects continued growth in ARR and paying customers, supported by product innovation and expansion into new markets.

• Anticipates maintaining a 20% compound annual revenue growth rate over the near term.

• Existing cash, cash equivalents, and short-term investments of $232.9 million are expected to be sufficient for at least the next 12 months.